FDA Approves Yet Another ORAL Tx for MS – Ponvory
Last week the FDA approved a new ORAL therapy, Ponvory (ponesimod) from Janssen Pharmaceutical, to treat relapsing forms of Multiple Sclerosis. There is no shortage
March 25, 2021
Last week the FDA approved a new ORAL therapy, Ponvory (ponesimod) from Janssen Pharmaceutical, to treat relapsing forms of Multiple Sclerosis. There is no shortage
Integrated specialty pharmacy services sound so upbeat it is hard to, well, beat. The integration being promoted by health system specialty pharmacies launched in recent
Everyone in the specialty pharmacy business sits up and pays attention whenever a specialty pharmacy is acquired or announces big news. After all, good competition
Last week the FDA approved a new ORAL Oncology therapy, Fotivda (tivozanib) from Aveo Oncology, for the treatment of adult patients with relapsed or refractory
Some years ago, payers demanded that specialty pharmacies obtain accreditation to even be considered for inclusion in their specialty pharmacy networks. It was an effective blocking
Almost ten years ago we started to raise the alarm of the threat that hospital-owned and operated specialty pharmacies pose to the Specialty Pharmacy (SP)
The FDA approved a new infused specialty therapy last week, Pepaxto (melphalan flufenamide) from Oncopeptides AB, for patients with relapsed or refractory multiple myeloma following
The FDA approved a new infused therapy last week, Amondys 45 (casimersen)) from Sarepta Therapeutics, with an indication for Duchenne Muscular Dystrophy (DMD). Amondys is
Earlier this month the FDA approved another infused specialty therapy, Cosela (trilaciclib) from G1 Therapeutics. It is the first therapy in its class to reduce
As readers of the AntonRx Report may know, we scan hundreds of articles each week to sleuth out information that is timely and important to
